Innovent Biologics' A-shares and H-shares both rose, with A-shares up nearly 2% and H-shares turning positive; the company's wholly-owned subsidiary signed a licensing agreement with Eli Lilly, which includes milestone payments of up to US$3.25 billi

2026-09-24

Innovent Biologics' A-shares and H-shares both rose, with A-shares up nearly 2% and H-shares turning positive; the company's wholly-owned subsidiary signed a licensing agreement with Eli Lilly, which includes milestone payments of up to US$3.25 billion.